This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...
Veradermics is keeping pace in an already high-octane year. | Topline results show the biotech's lead asset, VDPHL01, ...
The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium | The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K ...
Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche. | Amid a steady advance of kidney-focused label expansions, ...
Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results